Yarrow Bioscience Inc
Yarrow Bioscience Inc
Your view on YARW
Overview
What the company does, where it operates, and who runs it.
About Yarrow Bioscience Inc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Domzalski
- Headquarters
- 470 James Street, Suite 007, New Haven, CT, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Domzalski
- Headquarters
- 470 James Street, Suite 007, New Haven, CT, US
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases.
The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Yarrow Bioscience Inc from FRC's valuation model, read against the market price. YARW last traded at $19.63; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Yarrow Bioscience Inc. Starting points for Yarrow Bioscience Inc: EPS -$21.81, beta 2.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Yarrow Bioscience Inc. Yarrow Bioscience Inc paid $20.10 per share over the last year — a 102.4% yield at the current $19.63 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Yarrow Bioscience Inc. Trailing twelve-month EPS for Yarrow Bioscience Inc stands at -$21.81. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$5.75
Median
$5.75
High
$5.75
Average target
Analyst Ratings
- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.71 | -$0.93 | -$3.39 | -$5.88 |
| Low estimate | -$0.71 | -$0.93 | -$3.39 | -$5.88 |
| High estimate | -$0.71 | -$0.93 | -$3.39 | -$5.88 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$8.50 | -$7.26 | -$30.96 | — |
| Growth | +91.6% | +87.3% | +89.1% | — |
Revenue Estimate
| Revenue | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $200000.00 | $200000.00 | $530181.00 | $493143.00 |
| Low estimate | $200000.00 | $200000.00 | $530181.00 | $493143.00 |
| High estimate | $200000.00 | $200000.00 | $530181.00 | $493143.00 |
| No. of analysts | 1 | 1 | 3 | 3 |
| Year-ago revenue | $169000.00 | $130000.00 | $570000.00 | — |
| Growth | +18.3% | +53.8% | -7.0% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 13, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Yarrow Bioscience Inc. Yarrow Bioscience Inc has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Yarrow Bioscience Inc valued side by side against its closest peers. Yarrow Bioscience Inc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Yarrow Bioscience Inc executives and directors. Shares of Yarrow Bioscience Inc have traded between $14.05 and $46.95 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Yarrow Bioscience Inc. Coverage tracks Yarrow Bioscience Inc within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Yarrow Bioscience Inc.